NEUROCOGNITIVE DISORDERS: Edited by Perminder S. SachdevCannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementiaSherman, Chelseaa,b; Ruthirakuhan, Myuria,b; Vieira, Danielleb; Lanctôt, Krista L.a,b,c; Herrmann, Nathanb,cAuthor Information aDepartment of Pharmacology and Toxicology, University of Toronto bNeuropsychopharmacology Research Group, Hurvitz Brain Sciences Program, Sunnybrook Research Institute cDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada Correspondence to Dr Nathan Herrmann, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Room FG19, Toronto, ON, Canada M4N 3M5. Tel: +1 416 480 6100x6133; fax: +1 416 480 6022; e-mail: firstname.lastname@example.org Current Opinion in Psychiatry: March 2018 - Volume 31 - Issue 2 - p 140-146 doi: 10.1097/YCO.0000000000000399 Buy Metrics Abstract Purpose of review Efficacious treatment for neuropsychiatric symptoms (NPS), pain and weight loss for dementia patients is desperately needed. This review presents an up-to-date look at the literature investigating the use of cannabinoid for these symptoms in dementia. Recent findings We searched electronically for publications regarding cannabinoid use in dementia, with a focus on Alzheimer's disease. Seven studies and one case report have been conducted to examine the use of cannabinoids for the treatment of NPS of dementia, and three of these trials reported on the effect of cannabinoids on weight. Five studies reported decreased agitation or improvements in sleep with cannabinoid use. One crossover trial found that cannabinoids positively impacted weight, whereas a chart review study found no impact on weight with cannabinoids, but an increase in food intake. There were no trials examining the use of cannabinoids for pain in dementia. Summary Findings from trials with small sample sizes and various clinical populations suggest that cannabinoid use may be well tolerated and effective for treatment of NPS such as agitation as well as weight and pain management in patients with dementia. Additional studies are necessary to further elucidate the relative risks and benefits of this treatment. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.